Economics of Innovation

Optimal innovation balances willingness and ability to pay with the benefits of future R&D. Our wide-ranging programme aims to promote innovation in health care, increase our understanding of its value, and encourage R&D. New models of innovation should streamline development, reduce costs, and speed patient benefit.

Publication

Exploring the Interdependency between Public and Charitable Medical Research

1 April 2011

Continuing concern about the fiscal deficit makes it likely that government funding of health and medical research will remain under scrutiny. This OHE Consulting study, commissioned…

354 - IncentivesForRDAntimic_April2011_BIG
Publication

Incentives for R&D for New Antimicrobial Drugs

1 April 2011

Antimicrobial resistance (AMR) is becoming a major global public health threat and has begun to command attention from European and US policy makers. An initial focus…

349 - PharmaPricing_Differential_Feb11_OP_01_BIG
Publication

Pharmaceutical Pricing in Europe: Is Differential Pricing a Win-Win Solution?

1 February 2011

This paper examines the potentially positive impact of differential pricing in Europe and the overall negative effects of international reference pricing (IRP) measures. The authors point…

348 - priorityreview
Publication

Priority Review Vouchers to Encourage Innovation for Neglected Diseases

1 January 2011

Priority Review Vouchers (PRVs) are awarded in the US to companies that gain approval there for a new drug for one of sixteen tropical diseases, under…

News

Seminar Briefing on Science Policy

23 December 2010

At a recent OHE seminar, Prof Ben Martin (Science and Technology Policy Studies at SPRU, University of Sussex) presented the results of his extensive literature review…

News

Report on Orphan Drugs Released

9 December 2010

OHE Consulting has released new research on orphan medicinal products (OMPs) in Europe that assesses the effects of the European Union’s 1999 Regulation on Orphan Medicinal…

News

Access to Orphan Drugs in the EU

21 October 2010

Legislation in the EU provides incentives for the developmeng of drugs for rare diseases, known as orphan medicinal products (OMPs). At a recent conference, OHE’s Dr…

News

Biomedical and Health Research Spillovers in the UK

14 October 2010

Research spillovers exist when research by one organisation creates increased output for other organisations that operate in the same or other sector of the economy. Given…

Pryia Sharma
News

New Antimicrobial Drugs: EU Policy Options

4 October 2010

Antimicrobial resistance to drugs is a growing global public health issue. The EU began a discussion in 2009 about which policies can best encourage the development…